BMSC上清对治疗大鼠急性肝衰竭的临床研究分析

目的：探讨骨髓间充质干细胞（BMSC）上清治疗大鼠急性肝衰竭（ALF）的疗效，为其临床应用提供理论依据。方法采用全骨髓贴壁筛选法培养SD大鼠BMSC并收集其上清。腹腔注射D-氨基半乳糖胺（D-gal）建立大鼠ALF模型；将造模成功的大鼠随机分为治疗组和对照组，分别将等体积的BMSC上清及0.9%氯化钠注射液（NS）腹腔注射治疗3d，比较两组动物的肝功能、肝组织病理改变和7d生存率。结果（1）7d存活率分别为：BMSC上清治疗组70%，对照组20%，有显著差异（P＜0.05）。（2）BMSC上清治疗组的ALT、AST、TBIL明显降低，而对照组肝功能损害无明显改变，二者比较有显著性差异（P〈0.01）。（3）BMSC上清治疗组肝脏病理组织学损害明显改善。结论 BMSC上清腹腔注射治疗可明显改善ALF大鼠的肝功能及肝脏组织学损害，提高ALF大鼠的存活率，为ALF的治疗提供了新的途径。

Analysis of BMSC Supernatant Clinical Study forTreatment of Acute Liver Failure

Objective To investigate the bone marrow mesenchymal stem cells（BMSC）supernatant tre atment of acute liver failure （ALF）in effect, provide a theoretical basis for clinical application. Methods Bone marrow adherent cultured rat BMSC SD screening method and collect the super-natant.Intraperitoneal injection of D-galactosamine（D-gal）ALF established rat model;successful model rats were randomly divided into treatment group and control group,the volume of BMSC supernatant ,respectively, and 0.9% sodium chloride injection solution （NS） by intraperitoneal injection 3d, comparing the two groups of animals liver function, pathological changes in liver tissue and 7d survival.Results （1）7d survival rates were ： BMSC supernatant 70% of the treatment group , 20% of the control group , there were significant differences （P〈0.05）. （2）ALT BMSC supernatant treatment group, AST, TBIL significantly reduced, while the control group did not change significantly impaired liver function, there was a significant difference （P〈0.01） between the two.（3）BMSC treated supernatant of liver histological damage significantly improved. Conclusion BMSC super-natant intraperitoneal injection therapy can significantly improve the ALF rat liver function and liver histological damage and improve survival in rats with ALF,ALF treatment to provide a new way.